Andrea Spallanzani

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

Eric Van Cutsem, Erika Martinelli, Stefano Cascinu et al. · The Oncologist · 2018 · 143 citations · Full text

Medicine, Oncology, Pharmacology +15

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

Jaume Capdevila, Nicola Fazio, Carlos López et al. · Journal of Clinical Oncology · 2021 · 113 citations · Full text

Medicine, Oncology, Pharmacology +16

Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes

Fotios Loupakis, Ilaria Depetris, Paola Biason et al. · The Oncologist · 2020 · 112 citations · Full text

Medicine, Immunology, Oncology +17

The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors

Francesca Corti, Sara Lonardi, Rossana Intini et al. · European Journal of Cancer · 2021 · 109 citations

Medicine, Immunology, Oncology +14

Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study

Davide Campana, Thomas Walter, Sara Pusceddu et al. · Endocrine · 2017 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17